All lobbying filings

ALNYLAM PHARMACEUTICALS, INC.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $450,000.00 expenses · posted Jul 20, 2026

Official filing document

Bills named in this filing 2

HR 1672
Maintaining Investments in New Innovation Act
HR 4993
Joe Fiandra Access to Home Infusion Act of 2025

Lobbying activity 3

Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing

Trade (domestic/foreign)

Issues relating to supply chain tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.